Safety and efficacy of the switch to generic mycophenolate mofetil and tacrolimus in heart transplant patients

摘要

Background: Generic immunosuppressants may offer economic advantages, but their use is still controversial. At our center, 55 heart transplant patients were switched from CellCept (R) to Myfenax Teva (R) (MT) (n=51, 18% female, 8.16.6yr post-transplantation) and/or Prograf (R) to Tacrolimus Sandoz (R) (TS) (n=17, 41% female, 6.65.8yr post-transplantation).